第 3 组肺动脉高压：从基础到临床。
Group 3 Pulmonary Hypertension: From Bench to Bedside.
机构信息
Division of Pulmonary, Critical Care and Sleep Medicine (N.S., C.E.V.), Brown University, Providence, RI.
Department of Pathology, Universities of Giessen and Marburg Lung Center (UGMLC), Justus-Liebig University, Germany (P.D.).
出版信息
Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28.
Abstract
Pulmonary hypertension (PH) because of chronic lung disease is categorized as Group 3 PH in the most recent classification system. Prevalence of these diseases is increasing over time, creating a growing need for effective therapeutic options. Recent approval of the first pulmonary arterial hypertension therapy for the treatment of Group 3 PH related to interstitial lung disease represents an encouraging advancement. This review focuses on molecular mechanisms contributing to pulmonary vasculopathy in chronic hypoxia, the pathology and epidemiology of Group 3 PH, the right ventricular dysfunction observed in this population and clinical trial data that inform the use of pulmonary vasodilators in Group 3 PH.
摘要
慢性肺部疾病引起的肺动脉高压（PH）在最新的分类系统中被归类为第 3 组 PH。这些疾病的患病率随着时间的推移而增加，因此需要有效的治疗选择。最近批准了第一种肺动脉高压治疗药物，用于治疗与间质性肺病相关的第 3 组 PH，这是一个令人鼓舞的进展。这篇综述重点介绍了慢性缺氧导致肺血管病变的分子机制、第 3 组 PH 的病理学和流行病学、该人群中观察到的右心室功能障碍以及临床试验数据，这些数据为第 3 组 PH 中使用肺血管扩张剂提供了信息。
相似文献
1
Group 3 Pulmonary Hypertension: From Bench to Bedside.第 3 组肺动脉高压：从基础到临床。
Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28.
2
Pulmonary hypertension in parenchymal lung disease.肺实质疾病相关肺动脉高压。
Heart Fail Clin. 2012 Jul;8(3):461-74. doi: 10.1016/j.hfc.2012.04.010.
3
Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies.缺氧相关和非缺氧相关的肺动脉高压——已有的和新的治疗方法
Cardiovasc Res. 2006 Oct 1;72(1):30-40. doi: 10.1016/j.cardiores.2006.07.025. Epub 2006 Aug 1.
4
A case of glucocorticoid-resistant adult Still's disease complicated by pulmonary hypertension and interstitial lung disease.1例糖皮质激素抵抗型成人斯蒂尔病合并肺动脉高压和间质性肺疾病。
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):182-187. doi: 10.1093/mrcr/rxac081.
5
Pulmonary hypertension in chronic lung disease and hypoxia.慢性肺部疾病与低氧血症相关性肺动脉高压
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
6
Pulmonary hypertension secondary to interstitial lung disease.特发性肺纤维化相关性肺动脉高压。
Expert Rev Respir Med. 2011 Apr;5(2):179-89. doi: 10.1586/ers.11.11.
7
Pulmonary hypertension and right heart dysfunction in chronic lung disease.慢性肺病中的肺动脉高压与右心功能不全
Biomed Res Int. 2014;2014:739674. doi: 10.1155/2014/739674. Epub 2014 Jul 24.
8
Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia.肺部疾病和/或缺氧所致肺动脉高压的医疗负担。
BMC Pulm Med. 2017 Apr 11;17(1):58. doi: 10.1186/s12890-017-0399-1.
9
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压与系统性硬化症相关肺动脉高压患者治疗后血流动力学反应及结局比较：特发性肺纤维化相关肺动脉高压预后因素研究数据。
Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.
10
Current management of patients with pulmonary hypertension and right ventricular insufficiency.肺动脉高压合并右心室功能不全患者的当前管理
Curr Cardiol Rep. 2000 May;2(3):244-51. doi: 10.1007/s11886-000-0075-5.
引用本文的文献
1
Integrating CT-Based Lung Fibrosis and MRI-Derived Right Ventricular Function for the Detection of Pulmonary Hypertension in Interstitial Lung Disease.整合基于CT的肺纤维化和MRI衍生的右心室功能以检测间质性肺疾病中的肺动脉高压
J Clin Med. 2025 Jul 28;14(15):5329. doi: 10.3390/jcm14155329.
2
Opposing roles for myeloid and smooth muscle cell STING in pulmonary hypertension.髓系细胞和平滑肌细胞中的STING在肺动脉高压中的相反作用。
JCI Insight. 2025 May 22;10(13). doi: 10.1172/jci.insight.184792. eCollection 2025 Jul 8.
3
A Prospective Analysis of Vasoreactivity and Mortality in WHO Group 3 Pulmonary Hypertension.世界卫生组织第3组肺动脉高压血管反应性与死亡率的前瞻性分析
Pulm Circ. 2025 Apr 17;15(2):e70078. doi: 10.1002/pul2.70078. eCollection 2025 Apr.
4
TBX4 in Pulmonary Hypertension: Linking Lung Development to Precision Therapy.肺动脉高压中的TBX4：将肺发育与精准治疗联系起来
Am J Respir Cell Mol Biol. 2025 Sep;73(3):340-342. doi: 10.1165/rcmb.2025-0164ED.
5
Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).间质性肺疾病相关肺动脉高压（ILD-PH）的诊断与管理综述
J Clin Med. 2025 Mar 17;14(6):2029. doi: 10.3390/jcm14062029.
6
Oral Pulmonary Arterial Hypertension-Targeted Therapy in Patients With Pulmonary Hypertension due to Interstitial Lung Disease.间质性肺疾病所致肺动脉高压患者的口服肺动脉高压靶向治疗
J Clin Med Res. 2025 Mar;17(3):153-163. doi: 10.14740/jocmr6164. Epub 2025 Mar 10.
7
[Diagnosis and Treatment of Pulmonary Embolism and Pulmonary Hypertension in Patients With Interstitial Lung Disease].[间质性肺疾病患者肺栓塞和肺动脉高压的诊断与治疗]
Open Respir Arch. 2025 Feb 6;7(1):100406. doi: 10.1016/j.opresp.2025.100406. eCollection 2025 Jan-Mar.
8
Will Stub1 Be the Next Target for Pulmonary Hypertension Therapy Development?Will Stub1成为肺动脉高压治疗开发的下一个靶点？ （你原文中“Stub1”可能有误，推测是“STUB1”之类的准确医学术语）
Am J Respir Cell Mol Biol. 2025 Sep;73(3):329-331. doi: 10.1165/rcmb.2025-0034ED.
9
Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment.肺动脉高压治疗的基础与靶向方法
Pharmaceutics. 2025 Feb 10;17(2):224. doi: 10.3390/pharmaceutics17020224.
10
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.与肺部疾病和/或缺氧相关的3型肺动脉高压的病理生理学
Int J Mol Sci. 2025 Jan 20;26(2):835. doi: 10.3390/ijms26020835.
本文引用的文献
1
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.INCREASE 试验中吸入曲前列尼尔治疗特发性肺纤维化相关性肺动脉高压患者多疾病进展事件的疗效。
Am J Respir Crit Care Med. 2022 Jan 15;205(2):198-207. doi: 10.1164/rccm.202107-1766OC.
2
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.肺移植候选人选择的共识文件：国际心肺移植学会的更新。
J Heart Lung Transplant. 2021 Nov;40(11):1349-1379. doi: 10.1016/j.healun.2021.07.005. Epub 2021 Jul 24.
3
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.肺血管阻力可预测与间质性肺疾病相关的肺动脉高压患者的死亡率：来自COMPERA注册研究的结果
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.01483-2021. Print 2021 Aug.
4
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.吸入性曲前列尼尔与用力肺活量在间质性肺疾病合并肺动脉高压患者中的相关性：INCREASE 研究的事后分析。
Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29.
5
Elevated pulmonary vascular resistance predicts mortality in COPD patients.肺血管阻力升高预示慢性阻塞性肺疾病患者的死亡率。
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.00944-2021. Print 2021 Aug.
6
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).COPD 患者的肺动脉高压：来自新发起的肺动脉高压治疗比较前瞻性登记研究（COMPERA）的结果。
Chest. 2021 Aug;160(2):678-689. doi: 10.1016/j.chest.2021.02.012. Epub 2021 Feb 11.
7
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压患者应用吸入曲前列尼尔治疗
N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13.
8
Bayesian Inference Associates Rare Variants with Specific Phenotypes in Pulmonary Arterial Hypertension.贝叶斯推理将罕见变异与肺动脉高压的特定表型相关联。
Circ Genom Precis Med. 2020 Dec 15;14(1):e003155. doi: 10.1161/CIRCGEN.120.003155.
9
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.“往返之旅”——肺动脉高压的正向遗传学与反向表型分析。
Genes (Basel). 2020 Nov 26;11(12):1408. doi: 10.3390/genes11121408.
10
Pulmonary Artery Endovascular Device Compensates for Loss of Vascular Compliance in Pulmonary Arterial Hypertension.肺动脉血管内装置可补偿肺动脉高压中血管顺应性的丧失。
J Am Coll Cardiol. 2020 Nov 10;76(19):2284-2286. doi: 10.1016/j.jacc.2020.08.080.
Zotero 插件